Abstract 69TiP
Background
The incidence of breast cancer in Asia is rising. Recent advances in hormone receptor (HR) positive and human epidermal growth factor receptor negative advanced breast cancer (aBC) includes introduction of the CDK 4/6 inhibitors. Palbociclib was the first drug in this class to be introduced in Asia and is approved for use in aBC in combination with aromatase inhibitors (P+AI) as initial endocrine based therapy in postmenopausal women or with fulvestrant (P+F) in women with disease progression following endocrine therapy. Globally, there has been evaluations in the real world setting for palbociclib. However, data published for Asian patients in this setting remains scarce.
Trial design
Study Design: A prospective, observational, non-interventional, multi-centre study. A smartphone-based mobile application to collect patient-reported outcomes (PROs) associated with aBC and its treatment on Palbociclib has been developed. The impact of aBC and associated treatment of symptoms, functioning and quality of life (QOL) as reported by patients will be studied. Clinical data on therapy management, occurrence of neutropenia and any association between neutropenia, quality of life and PROs will also be captured. Eligibility Criteria: Women with HR+/HER2– aBC receiving P+AI or P+F as per approved indication in their country. Aims and Objectives: Primary objectives are to assess and describe clinical and PROs in eligible patient population. 12-Item ‘Short Form Health Survey’ & ‘Center for Epidemiological Studies Depression Scale’ would be used. The study will also document changes in therapy as well as the incidence, severity, and duration of neutropenia through data recorded from patient’s medical records. Statistical Methods: For the purpose of this study, analyses will generally be descriptive in nature and will be conducted using SAS statistical software Present Accrual and Target Accrual: Approximately 100 patients from up to 12 sites within 4 Asian countries (Taiwan, India, Malaysia and Hong Kong) will be enrolled. Study duration will be approximately 12 months assuming 6 months of recruitment. The study is open in all 4 participating countries with 7 patients recruited so far.
Clinical trial identification
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
M. Singh, J. Binko, M. Alam: Shareholder/Stockholder/Stock options, Full/Part-time employment: Pfizer Inc. K. Lilly, S. Chang: Full/Part-time employment: Parexel International Pty Ltd. S. Bowles: Full/Part-time employment: Intouch Solutions. All other authors have declared no conflicts of interest.
Resources from the same session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session